Your browser doesn't support javascript.
loading
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Jiang, Haiping; Zheng, Yulong; Qian, Jiong; Mao, Chenyu; Xu, Xin; Li, Ning; Xiao, Cheng; Wang, Huan; Teng, Lisong; Zhou, Hui; Wang, Shuyan; Zhu, Donglei; Sun, Tao; Yu, Yingying; Guo, Wenying; Xu, Nong.
Afiliación
  • Jiang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Zheng Y; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Qian J; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Mao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Xu X; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Li N; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Xiao C; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Wang H; Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003, China.
  • Teng L; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Zhou H; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Wang S; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Zhu D; Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc, Suzhou, China.
  • Sun T; Hangzhou ImmuQuad Biotechnologies, Hangzhou, China.
  • Yu Y; Zhejiang-California International NanoSystems Institute, Zhejiang University, Hangzhou, China.
  • Guo W; Hangzhou ImmuQuad Biotechnologies, Hangzhou, China.
  • Xu N; Hangzhou ImmuQuad Biotechnologies, Hangzhou, China.
Cancer Immunol Immunother ; 70(3): 857-868, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33070260
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2021 Tipo del documento: Article